Evidence map›Paper›PMID 26181626›Full record

ArticleGene therapy2016

Evaluation of helper-dependent canine adenovirus vectors in a 3D human CNS model.

D Simão, C Pinto, P Fernandes, C J Peddie, S Piersanti, L M Collinson, S Salinas, I Saggio, G Schiavo, E J Kremer and 2 more

Open access · bronzeAbstract read
In one paragraph

Article in Gene therapy, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 22 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. The Relationship Between Vitamin B6, Diabetes and Cancer.Frontiers in genetics · 2018 · on this map
    Review
  10. Article
  11. Article
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 9 institutions in 4 countries.

D SimãoiBET-Instituto de Biologia Experimental e Tecnológica, Oeiras, Portugal.
C PintoiBET-Instituto de Biologia Experimental e Tecnológica, Oeiras, Portugal.
P FernandesiBET-Instituto de Biologia Experimental e Tecnológica, Oeiras, Portugal.
C J PeddieThe Francis Crick Institute, Lincoln's Inn Fields Laboratory, London, UK.
S PiersantiDipartimento di Biologia e Biotecnologie 'Charles Darwin', Università di Roma La Sapienza, Rome, Italy.
L M CollinsonThe Francis Crick Institute, Lincoln's Inn Fields Laboratory, London, UK.
S SalinasInstitut de Génétique Moléculaire de Montpellier, Montpellier, France.
I SaggioDipartimento di Biologia e Biotecnologie 'Charles Darwin', Università di Roma La Sapienza, Rome, Italy.
G SchiavoSobell Department of Motor Neuroscience and Movement Disorders, Institute of Neurology, University College London, London, UK.
E J KremerInstitut de Génétique Moléculaire de Montpellier, Montpellier, France.
C BritoiBET-Instituto de Biologia Experimental e Tecnológica, Oeiras, Portugal.
P M AlvesiBET-Instituto de Biologia Experimental e Tecnológica, Oeiras, Portugal.
Universidade Nova de Lisboa · PTInstituto de Biologia Experimental e Tecnológica · PTInstitut de Génétique Moléculaire de Montpellier · FRInstitute of Molecular Biology and Pathology · ITSapienza University of Rome · ITSobell House · GBThe Francis Crick Institute · GBThe Honourable Society of Lincoln's Inn · GBUniversité de Montpellier · FR

Funding

Medical Research Council FC001999Medical Research Council MR/K01580X/1
6 · The paper itself

Abstract

Gene therapy is a promising approach with enormous potential for treatment of neurodegenerative disorders. Viral vectors derived from canine adenovirus type 2 (CAV-2) present attractive features for gene delivery strategies in the human brain, by preferentially transducing neurons, are capable of efficient axonal transport to afferent brain structures, have a 30-kb cloning capacity and have low innate and induced immunogenicity in preclinical tests. For clinical translation, in-depth preclinical evaluation of efficacy and safety in a human setting is primordial. Stem cell-derived human neural cells have a great potential as complementary tools by bridging the gap between animal models, which often diverge considerably from human phenotype, and clinical trials. Herein, we explore helper-dependent CAV-2 (hd-CAV-2) efficacy and safety for gene delivery in a human stem cell-derived 3D neural in vitro model. Assessment of hd-CAV-2 vector efficacy was performed at different multiplicities of infection, by evaluating transgene expression and impact on cell viability, ultrastructural cellular organization and neuronal gene expression. Under optimized conditions, hd-CAV-2 transduction led to stable long-term transgene expression with minimal toxicity. hd-CAV-2 preferentially transduced neurons, whereas human adenovirus type 5 (HAdV5) showed increased tropism toward glial cells. This work demonstrates, in a physiologically relevant 3D model, that hd-CAV-2 vectors are efficient tools for gene delivery to human neurons, with stable long-term transgene expression and minimal cytotoxicity.

Indexed as

Genetic VectorsTransduction, GeneticAdenoviruses, CanineAdenoviruses, HumanAnimalsAxonal TransportCell DifferentiationCell SurvivalCentral Nervous SystemCloning, MolecularDisease Models, AnimalGene Expression RegulationGenetic TherapyGene Transfer TechniquesHumansNeural Stem Cells

Identifiers

PMID26181626
PMCPMC5367519
OpenAlexW915821751

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.